Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience

Journal of Pediatric Surgery

Volumn 45, Issue 4, 2010, Pages 678-686

  Robbins, Jared R ^a   Krasin, Matthew J ^a   Pai Panandiker, Atmaram S ^a   Watkins, Amy ^a   Wu, Jianrong ^a   Santana, Victor M ^a,b   Furman, Wayne L ^a,b   Davidoff, Andrew M ^a,b   McGregor, Lisa M ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Neoplasm recurrence, local; Neuroblastoma; Radiotherapy; Survival

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ARTICLE; CANCER CONTROL; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 77950471784     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpedsurg.2009.11.003     Document Type: Article

References (35)

1. Berthold F., Hero B., Kremens B., et al. Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett 197 1-2 (2003) 11-17
2. De Bernardi B., Nicolas B., Boni L., et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J Clin Oncol 21 8 (2003) 1592-1601
3. Kaneko M., Tsuchida Y., Mugishima H., et al. Intensified chemotherapy increases the survival rates in patients with stage 4 neuroblastoma with MYCN amplification. J Pediatr Hematol Oncol 24 8 (2002) 613-621
4. Matthay K.K., Reynolds C.P., Seeger R.C., et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study. J Clin Oncol 27 7 (2009) 1007-1013
5. Nitschke R., Smith E.I., Shochat S., et al. Localized neuroblastoma treated by surgery: a Pediatric Oncology Group study. J Clin Oncol 6 8 (1988) 1271-1279
6. Adkins E.S., Sawin R., Gerbing R.B., et al. Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. J Pediatr Surg 39 6 (2004) 931-936
7. McGregor L.M., Rao B.N., Davidoff A.M., et al. The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children's Research Hospital experience. Cancer 104 12 (2005) 2837-2846
8. von Schweinitz D., Hero B., and Berthold F. The impact of surgical radicality on outcome in childhood neuroblastoma. Eur J Pediatr Surg 12 6 (2002) 402-409
9. La Quaglia M.P., Kushner B.H., Su W., et al. The impact of gross total resection on local control and survival in high-risk neuroblastoma. J Pediatr Surg 39 3 (2004) 412-417
10. Bradfield S.M., Douglas J.G., Hawkins D.S., et al. Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma. Cancer 100 6 (2004) 1268-1275
11. Haas-Kogan D.A., Swift P.S., Selch M., et al. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys 56 1 (2003) 28-39
12. Kushner B.H., Wolden S., LaQuaglia M.P., et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol 19 11 (2001) 2821-2828
13. Marcus K.J., Shamberger R., Litman H., et al. Primary tumor control in patients with stage 3/4 unfavorable neuroblastoma treated with tandem double autologous stem cell transplants. J Pediatr Hematol Oncol 25 12 (2003) 934-940
14. Paulino A.C., Mayr N.A., Simon J.H., and Buatti J.M. Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity. Int J Radiat Oncol Biol Phys 52 4 (2002) 1025-1031
15. Rosen E.M., Cassady J.R., Frantz C.N., et al. Neuroblastoma: the Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/Children's Hospital experience. J Clin Oncol 2 7 (1984) 719-732
16. Wolden S.L., Gollamudi S.V., Kushner B.H., et al. Local control with multimodality therapy for stage 4 neuroblastoma. Int J Radiat Oncol Biol Phys 46 4 (2000) 969-974
17. De Bernardi B., Pianca C., Pistamiglio P., et al. Neuroblastoma with symptomatic spinal cord compression at diagnosis: treatment and results with 76 cases. J Clin Oncol 19 1 (2001) 183-190
18. Paulino A.C. Palliative radiotherapy in children with neuroblastoma. Pediatr Hematol Oncol 20 2 (2003) 111-117
19. Flandin I., Hartmann O., Michon J., et al. Impact of TBI on late effects in children treated by megatherapy for stage IV neuroblastoma. A study of the French Society of Pediatric oncology. Int J Radiat Oncol Biol Phys 64 5 (2006) 1424-1431
20. Brodeur G.M., Pritchard J., Berthold F., et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11 8 (1993) 1466-1477
21. Shimada H., Ambros I.M., Dehner L.P., et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 86 2 (1999) 364-372
22. Alvarado C.S., London W.B., Look A.T., et al. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group study. J Pediatr Hematol Oncol 22 3 (2000) 197-205
23. Brodeur G.M., Seeger R.C., Schwab M., et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224 4653 (1984) 1121-1124
24. Shapiro D.N., Valentine M.B., Rowe S.T., et al. Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma. Am J Pathol 142 5 (1993) 1339-1346
25. Gray R.J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Annals of Statistics 16 3 (1988) 1141-1154
26. Kaplan E.L., and Meier P. Nonparametric-estimation from incomplete observations. Journal of the American Statistical Association 53 282 (1958) 457-481
27. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical-trials requiring prolonged observation of each patient .2. Analysis and examples. British Journal of Cancer 35 1 (1977) 1-39
28. Matthay K.K., Atkinson J.B., Stram D.O., et al. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Children's Cancer Group pilot study. J Clin Oncol 11 11 (1993) 2226-2233
29. Kushner B.H., O'Reilly R.J., Mandell L.R., et al. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol 9 2 (1991) 274-279
30. Matthay K.K., Yanik G., Messina J., et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol 25 9 (2007) 1054-1060
31. Yu A.L., Uttenreuther-Fischer M.M., Huang C.S., et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 16 6 (1998) 2169-2180
32. Kushner B.H., Kramer K., and Cheung N.K. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 19 22 (2001) 4189-4194
33. Osenga K.L., Hank J.A., Albertini M.R., et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 12 6 (2006) 1750-1759
34. Dickson P.V., Hamner J.B., Sims T.L., et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 13 13 (2007) 3942-3950
35. George R.E., Sanda T., Hanna M., et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455 7215 (2008) 975-978